Lixivaptan BALANCE study is a 650-patient Phase III, global, multi-center, randomized, placebo-controlled, double-blind, study of lixivaptan for hyponatremia in patients with heart failure. The primary objective is to evaluate the safety and effectiveness of lixivaptan, when compared to the placebo, in increasing serum sodium from baseline in heart failure patients with hyponatremia. In previous studies, lixivaptan improved blood sodium levels, lowered body weight and increased urine volume. Those studies suggest that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with heart failure, Syndrome of Inappropriate Anti-Diuretic Hormone(SIADH), and Liver Cirrhosis with
Scarlet fever serum Scarlet fever serum Scarlet fever serum was used beginning in November 1900 after its development in the Sero-Therapeutic Laboratory of Rudolph Hospital in Vienna, Austria. The serum was taken from the blood of horses. Infected children were injected in their abdominal skin by Dr. Paul Moser. Mortality rates from scarlet fever declined significantly following the use of the blood serum. Moser at first used scarlet fever serum primarily on the most severely sick persons. After achieving positive results it was applied in the first or second day following contraction of scarlet fever. In many cases the children treated demonstrated great